The abstract is read at the publisher; the summary is JClub's.
In hospitalized acute heart failure, clinically diagnosed ototoxicity occurred in 2.7% of 608 admissions, and peak IV loop diuretic dose (≥160 or ≥400 mg furosemide equivalents) was not linked to higher risk.
- Why it matters: Clinicians limit loop diuretic dosing in heart failure due to fear of ear injury, but the true relationship between dose and lasting versus temporary hearing effects is unclear.
- What they did: Cohort 1 (50 stable outpatients) used serial audiometry during randomized IV bumetanide dosing (1.25–10 mg), and Cohort 2 (40 hospitalized patients) used serial audiometry during IV furosemide up to 500 mg; Cohort 3 (22 656 hospitalized) used ICD-10–coded ototoxicity with multivariable dose analyses.
- The result: Temporary hearing shifts were infrequent in Cohort 1 (6% of 400 doses) and largely resolved within hours (absent in 98% of measurements), with dose linked only at peak concentration; Cohorts 2 and 3 found no dose association with ototoxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.